Nationwide survey of the outcomes of living donor liver transplantation for hepatoblastoma in Japan

Seisuke Sakamoto, Mureo Kasahara, Koichi Mizuta, Tatsuo Kuroda, Takahito Yagi, Tomoaki Taguchi, Yukihiro Inomata, Koji Umeshita, Shinji Uemoto

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Recently, liver transplantation (LT) has been increasingly performed for unresectable hepatoblastoma (HB) with acceptable results. We conducted a national survey of cases undergoing living donor liver transplantation (LDLT) for HB to evaluate their outcomes. Thirty-nine patients (28 males and 11 females with a median age at LDLT of 3.6 years) who had undergone LDLT for HB by the end of 2009 were enrolled in this study. The clinical data were collected from their medical records via a questionnaire survey in 2011 (median follow-up = 4.6 years). Thirteen patients (33.3%) had extrahepatic lesions before LDLT. Thirty-eight patients (97.4%) received chemotherapy, and 15 (38.5%) underwent hepatectomy before LDLT. Twenty-seven patients (69.2%) were alive without recurrence after LDLT, and 12 patients (30.8%) suffered from recurrence. The most common site of recurrence was the lung (9 cases), which was followed by the graft liver (6 cases). The median interval from LDLT to recurrence was 5.5 months. Four of the 9 cases (44.4%) with lung metastasis underwent surgical resection, and 3 were alive without any tumor recurrence. Eight patients died because of tumor recurrence. The multivariate landmark analysis revealed that the independent recurrence risk factors were a high alpha-fetoprotein (AFP) level at diagnosis [≥500,000 ng/mL; hazard ratio (HR) = 7.86, P = 0.010], the presence of extrahepatic lesions before LDLT (HR = 3.82, P = 0.042), and a high AFP level at LDLT (≥4000 ng/mL; HR = 9.19, P = 0.036). The actuarial 3- and 5-year patient survival rates were 84.3% and 77.3%, respectively. In conclusion, with appropriate timing for scheduled LT, LDLT provides a valuable alternative treatment with excellent results for children with HB.

Original languageEnglish
Pages (from-to)333-346
Number of pages14
JournalLiver Transplantation
Volume20
Issue number3
DOIs
Publication statusPublished - 2014 Mar

Fingerprint

Hepatoblastoma
Living Donors
Liver Transplantation
Japan
Recurrence
alpha-Fetoproteins
Surveys and Questionnaires
Lung
Hepatectomy
Medical Records
Neoplasms

ASJC Scopus subject areas

  • Surgery
  • Transplantation
  • Hepatology

Cite this

Nationwide survey of the outcomes of living donor liver transplantation for hepatoblastoma in Japan. / Sakamoto, Seisuke; Kasahara, Mureo; Mizuta, Koichi; Kuroda, Tatsuo; Yagi, Takahito; Taguchi, Tomoaki; Inomata, Yukihiro; Umeshita, Koji; Uemoto, Shinji.

In: Liver Transplantation, Vol. 20, No. 3, 03.2014, p. 333-346.

Research output: Contribution to journalArticle

Sakamoto, S, Kasahara, M, Mizuta, K, Kuroda, T, Yagi, T, Taguchi, T, Inomata, Y, Umeshita, K & Uemoto, S 2014, 'Nationwide survey of the outcomes of living donor liver transplantation for hepatoblastoma in Japan', Liver Transplantation, vol. 20, no. 3, pp. 333-346. https://doi.org/10.1002/lt.23803
Sakamoto, Seisuke ; Kasahara, Mureo ; Mizuta, Koichi ; Kuroda, Tatsuo ; Yagi, Takahito ; Taguchi, Tomoaki ; Inomata, Yukihiro ; Umeshita, Koji ; Uemoto, Shinji. / Nationwide survey of the outcomes of living donor liver transplantation for hepatoblastoma in Japan. In: Liver Transplantation. 2014 ; Vol. 20, No. 3. pp. 333-346.
@article{28eb10f4a6684871b338565ccd02a4ce,
title = "Nationwide survey of the outcomes of living donor liver transplantation for hepatoblastoma in Japan",
abstract = "Recently, liver transplantation (LT) has been increasingly performed for unresectable hepatoblastoma (HB) with acceptable results. We conducted a national survey of cases undergoing living donor liver transplantation (LDLT) for HB to evaluate their outcomes. Thirty-nine patients (28 males and 11 females with a median age at LDLT of 3.6 years) who had undergone LDLT for HB by the end of 2009 were enrolled in this study. The clinical data were collected from their medical records via a questionnaire survey in 2011 (median follow-up = 4.6 years). Thirteen patients (33.3{\%}) had extrahepatic lesions before LDLT. Thirty-eight patients (97.4{\%}) received chemotherapy, and 15 (38.5{\%}) underwent hepatectomy before LDLT. Twenty-seven patients (69.2{\%}) were alive without recurrence after LDLT, and 12 patients (30.8{\%}) suffered from recurrence. The most common site of recurrence was the lung (9 cases), which was followed by the graft liver (6 cases). The median interval from LDLT to recurrence was 5.5 months. Four of the 9 cases (44.4{\%}) with lung metastasis underwent surgical resection, and 3 were alive without any tumor recurrence. Eight patients died because of tumor recurrence. The multivariate landmark analysis revealed that the independent recurrence risk factors were a high alpha-fetoprotein (AFP) level at diagnosis [≥500,000 ng/mL; hazard ratio (HR) = 7.86, P = 0.010], the presence of extrahepatic lesions before LDLT (HR = 3.82, P = 0.042), and a high AFP level at LDLT (≥4000 ng/mL; HR = 9.19, P = 0.036). The actuarial 3- and 5-year patient survival rates were 84.3{\%} and 77.3{\%}, respectively. In conclusion, with appropriate timing for scheduled LT, LDLT provides a valuable alternative treatment with excellent results for children with HB.",
author = "Seisuke Sakamoto and Mureo Kasahara and Koichi Mizuta and Tatsuo Kuroda and Takahito Yagi and Tomoaki Taguchi and Yukihiro Inomata and Koji Umeshita and Shinji Uemoto",
year = "2014",
month = "3",
doi = "10.1002/lt.23803",
language = "English",
volume = "20",
pages = "333--346",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Nationwide survey of the outcomes of living donor liver transplantation for hepatoblastoma in Japan

AU - Sakamoto, Seisuke

AU - Kasahara, Mureo

AU - Mizuta, Koichi

AU - Kuroda, Tatsuo

AU - Yagi, Takahito

AU - Taguchi, Tomoaki

AU - Inomata, Yukihiro

AU - Umeshita, Koji

AU - Uemoto, Shinji

PY - 2014/3

Y1 - 2014/3

N2 - Recently, liver transplantation (LT) has been increasingly performed for unresectable hepatoblastoma (HB) with acceptable results. We conducted a national survey of cases undergoing living donor liver transplantation (LDLT) for HB to evaluate their outcomes. Thirty-nine patients (28 males and 11 females with a median age at LDLT of 3.6 years) who had undergone LDLT for HB by the end of 2009 were enrolled in this study. The clinical data were collected from their medical records via a questionnaire survey in 2011 (median follow-up = 4.6 years). Thirteen patients (33.3%) had extrahepatic lesions before LDLT. Thirty-eight patients (97.4%) received chemotherapy, and 15 (38.5%) underwent hepatectomy before LDLT. Twenty-seven patients (69.2%) were alive without recurrence after LDLT, and 12 patients (30.8%) suffered from recurrence. The most common site of recurrence was the lung (9 cases), which was followed by the graft liver (6 cases). The median interval from LDLT to recurrence was 5.5 months. Four of the 9 cases (44.4%) with lung metastasis underwent surgical resection, and 3 were alive without any tumor recurrence. Eight patients died because of tumor recurrence. The multivariate landmark analysis revealed that the independent recurrence risk factors were a high alpha-fetoprotein (AFP) level at diagnosis [≥500,000 ng/mL; hazard ratio (HR) = 7.86, P = 0.010], the presence of extrahepatic lesions before LDLT (HR = 3.82, P = 0.042), and a high AFP level at LDLT (≥4000 ng/mL; HR = 9.19, P = 0.036). The actuarial 3- and 5-year patient survival rates were 84.3% and 77.3%, respectively. In conclusion, with appropriate timing for scheduled LT, LDLT provides a valuable alternative treatment with excellent results for children with HB.

AB - Recently, liver transplantation (LT) has been increasingly performed for unresectable hepatoblastoma (HB) with acceptable results. We conducted a national survey of cases undergoing living donor liver transplantation (LDLT) for HB to evaluate their outcomes. Thirty-nine patients (28 males and 11 females with a median age at LDLT of 3.6 years) who had undergone LDLT for HB by the end of 2009 were enrolled in this study. The clinical data were collected from their medical records via a questionnaire survey in 2011 (median follow-up = 4.6 years). Thirteen patients (33.3%) had extrahepatic lesions before LDLT. Thirty-eight patients (97.4%) received chemotherapy, and 15 (38.5%) underwent hepatectomy before LDLT. Twenty-seven patients (69.2%) were alive without recurrence after LDLT, and 12 patients (30.8%) suffered from recurrence. The most common site of recurrence was the lung (9 cases), which was followed by the graft liver (6 cases). The median interval from LDLT to recurrence was 5.5 months. Four of the 9 cases (44.4%) with lung metastasis underwent surgical resection, and 3 were alive without any tumor recurrence. Eight patients died because of tumor recurrence. The multivariate landmark analysis revealed that the independent recurrence risk factors were a high alpha-fetoprotein (AFP) level at diagnosis [≥500,000 ng/mL; hazard ratio (HR) = 7.86, P = 0.010], the presence of extrahepatic lesions before LDLT (HR = 3.82, P = 0.042), and a high AFP level at LDLT (≥4000 ng/mL; HR = 9.19, P = 0.036). The actuarial 3- and 5-year patient survival rates were 84.3% and 77.3%, respectively. In conclusion, with appropriate timing for scheduled LT, LDLT provides a valuable alternative treatment with excellent results for children with HB.

UR - http://www.scopus.com/inward/record.url?scp=84896847142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896847142&partnerID=8YFLogxK

U2 - 10.1002/lt.23803

DO - 10.1002/lt.23803

M3 - Article

VL - 20

SP - 333

EP - 346

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 3

ER -